by TractManager | Apr 22, 2024 | Emerging Technology Report
ReCET (Endogenex Inc.) is an investigational endoscopic procedure that uses pulsed electric fields to promote duodenal mucosal regeneration for treatment of type 2 diabetes that is poorly controlled with oral medications and/or insulin.
by TractManager | Apr 17, 2024 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the Paradise Ultrasound Renal Denervation System (ReCor Medical Inc.) for reduction of blood pressure in patients...
by TractManager | Apr 17, 2024 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the Intracept Intraosseous Nerve Ablation System (Relievant Medsystems Inc.) for improvement in back pain and...
by TractManager | Apr 10, 2024 | Emerging Technology Report
The TriClip G4 System (Abbott Medical) is a transcatheter tricuspid valve repair system indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, who are at intermediate...
by TractManager | Apr 10, 2024 | Emerging Technology Report
Relyvrio (sodium phenylbutyrate/taurursodiol, formerly AMX0035; Amylyx Pharmaceuticals Inc.) is an oral fixed-dose combination drug indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults. As of April 4, 2024, Relyvrio has been withdrawn from the...
Recent Comments